Matko Kalac

[Matko Kalac @MatkoKalac]

Fresh off the press:
https://t.co/b9Cr4WyqSy

Please check out our publication on the efficacy of romidepsin and azacitidine in patients with peripheral T cell lymphoma (PTCL) when given in a real world setting.

@UCIrvineHealth @lymphomahub #PTCL #romidepsin #azacitidine #ASH

[Enrica Marchi @enrica_marchi]

Check out our new publication on the efficacy of azacitidine and romidepsin for patients with PTCL in a Real-World Experience ⁦@MatkoKalac⁩ ⁦@SalviaJain⁩ #ash #ptcl #lymphomahub #lymphoma #newdrugs https://t.co/Ex1hJjxJG7

[Matko Kalac @MatkoKalac]

@enrica_marchi @SalviaJain Great news for PTCL patients!

[Matko Kalac @MatkoKalac]

Marcher 1500km contre le virus HTLV-1 https://t.co/0yX5cz2I2l

[Firas El Chaer, MD, MSHCM @FirasElChaer]

What's My Doctor Thinking? Treating Secondary AML | Aplastic Anemia & MDS International Foundation

Join me tomorrow at 1pm EST

⁦@aamdsif⁩ ⁦@uvahealthnews⁩ ⁦@UVACancerCenter⁩ ⁦@UVA⁩ https://t.co/BAZHSF3IZK

[VJHemOnc @VJHemOnc]

We had a lovely interview with Matko Kalac (@IcahnMountSinai) on novel treatment approaches and unmet needs in T-cell lymphoma.

Watch our expert interviews now on https://t.co/O9p0vDBrzw!

@EHA_Hematology #EHA2022 #LymSM #HemOnc